Bourse

Revolutionizing Pulmonary Embolism Treatment: The Dawn of Ultrasound-Facilitated Thrombolysis A groundbreaking clinical trial, HI-PEITHO, has revealed a significant advancement in the treatment of intermediate-risk pulmonary embolism (PE). Results announced on March 28, 2026, demonstrate that the EKOS™ Endovascular System, developed by Boston Scientific, is superior to standard anticoagulation therapy alone. This marks a potential paradigm … Read more

European Markets Show Resilience Amidst Global Economic Shifts As of 10:21:55 AM CET on March 24, 2026, European markets are displaying a mixed performance. The CAC 40 is currently at 7,702.21, down 0.31%, while the Euronext 100 has decreased by 0.28% to 1,705.16. These figures reflect ongoing volatility as investors navigate a complex global economic … Read more

Zealand Pharma’s Petrelintide: A New Era in Obesity Treatment? Recent Phase 2 trial results for petrelintide, developed in collaboration between Zealand Pharma and Roche, are generating significant buzz in the pharmaceutical industry. The data, revealed on March 5, 2026, demonstrate a mean weight loss of up to 10.7% at 42 weeks, compared to 1.7% in … Read more

BioNTech Sues Moderna: A Sign of Escalating Battles Over mRNA Vaccine Technology A new legal battle has erupted in the pharmaceutical world, with German biotech firm BioNTech filing a lawsuit against Moderna in Delaware federal court. The core of the dispute centers on alleged patent infringement related to the mRNA vaccine technology that powered both … Read more

The Rise of Preventative Allergy Care: Polyrizon’s NASARIX™ and the Future of Nasal Defense The allergy treatment market is poised for significant growth, projected to reach USD 18.81 billion by 2035, according to recent estimates. This expansion isn’t just about stronger antihistamines; it’s driven by a growing demand for preventative, drug-free solutions. Polyrizon Ltd. (Nasdaq: … Read more

GSK’s Nucala Approval in China: A Glimpse into the Future of Personalized Respiratory Medicine The recent approval of GSK’s Nucala (mepolizumab) in China as an add-on treatment for chronic obstructive pulmonary disease (COPD) marks a significant step forward, not just for GSK, but for the evolving landscape of respiratory medicine globally. This isn’t simply about … Read more